You just clicked a link to go to another website. If you continue, you will leave this site and go to a site run by someone else.
Medtronic Canada does not review or control the content on the other website, and is not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site not be licensed for sale in Canada.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
By choosing to accept, you acknowledge that you are a Certified Healthcare Professional.
Understand sacral neuromodulation
patient selection criteria and discover
our complete portfolio of therapies.
Millions of people are living with bladder and bowel control problems.
Sacral neuromodulation (SNM) delivered by the InterStim™ systems is indicated for patients who have failed or could not tolerate more conservative treatments for one or more of the following conditions: overactive bladder, or OAB, (urge incontinence or urgency-frequency), non-obstructive urinary retention, and chronic fecal incontinence (FI).
Sacral neuromodulation (SNM) delivered by the InterStimTM system is indicated for patients who have failed or could not tolerate more conservative treatments for one or more of the following conditions: overactive bladder, or OAB, (urge incontinence or urgency-frequency), non-obstructive urinary retention, and chronic fecal incontinence (FI).
Bladder control candidates
Many patients with OAB or retention have poor or reduced quality of life because of their symptoms. These patients are considered suitable for the InterStim™ systems once they have failed or could not tolerate more conservative treatments.
This therapy is appropriate for bladder control patients who:
This therapy is not appropriate for bladder control patients who:
Bowel control candidates
Many patients with chronic FI have poor or reduced quality of life because of their symptoms. These patients are considered suitable for the InterStim™ systems if they have failed (or are not candidates for) more conservative treatments such as medication, behavior modifications, bowel retraining, and/or pelvic muscle training.
This therapy is most appropriate for bowel control patients who:
This therapy is not appropriate for bowel control patients who:
Safety and effectiveness of the InterStim™ systems for bladder and bowel control candidates has not been established for:
Take convenient courses specifically designed for clinicians treating patients with OAB, non- obstructive urinary retention, and chronic FI.
SEE COURSESHear from actual patients who achieve life-changing relief using the Medtronic InterStimTM systems.
Read the storiesResources and support practices you can use to improve efficiency and find opportunities for growth.
EMPOWER YOUR PRACTICEOur patient campaigns provide helpful education and resources, so patients stay informed and engaged throughout their journey to relief.
SEE HOW TO REGISTEROur patient campaigns provide helpful education and resources, so patients stay informed and engaged throughout their journey to relief.
SEE HOW TO REGISTERStewart WF, Van Rooyen JB, Cundiff GW, et al. World J Urol. 2003;20(6):327-336.
United Nations, Department of Economic and Social Affairs, Population Division (2011). World Population Prospects: The 2010 Revision, CD-ROM Edition.
United States Quick Facts. United States Census Bureau website. Available at: https://www.census.gov/quickfacts/table/PST045215/00. Accessed January 27, 2017.
Whitehead WE, Borrud L, Goode PS, et al. Fecal Incontinence in U.S. adults: epidemiology and risk factors. Gastroenterology. 2009;137(2):512–517.